Phase I study of bortezomib and 153Sm-lexidronam combination for refractory and relapsed multiple myeloma.

被引：0
|
作者：
Yeh, H. S.
Swift, R. A.
Ferretti, D.
Mapes, R. A.
Goeckeler, W. F.
Berenson, J. R.
机构：
[1] Inst Myeloma & Bone Canc Res, W Hollywood, CA USA
[2] Oncotheraoeut Inc, W Hollywood, CA USA
[3] Cytogen Corp, Princeton, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：450S / 450S
页数：1
相关论文
共 50 条
  • [31] Phase I study of pegylated liposomal doxorubicin in combination with bortezomib for Japanese patients with relapsed or refractory multiple myeloma
    Kusumoto, Shigeru
    Sunami, Kazutaka
    Inagaki, Mitsuo
    Iida, Shinsuke
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2015, 101 (06) : 578 - 584
  • [32] Updated results from BELLINI, a phase III study of venetoclax or placebo in combination with bortezomib and dexamethasone in relapsed/refractory multiple myeloma.
    Kumar, Shaji
    Harrison, Simon J.
    Cavo, Michele
    de La Rubia, Javier
    Popat, Rakesh
    Gasparetto, Cristina
    Hungria, Vania
    Salwender, Hans
    Suzuki, Kenshi
    Kim, Inho
    Gay, Francesca
    Mikala, Gabor
    Punnoose, Elizabeth
    Hong, Wan-Jen
    Sood, Anjla
    Jalaluddin, Muhammad
    Ross, Jeremy A.
    Pauff, James M.
    Maciag, Paulo Cesar
    Moreau, Philippe
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [33] A phase 1 trial of lenalidomide (REVLIMID®) with bortezomib (VELCADE®) in relapsed and refractory multiple myeloma.
    Richardson, P
    Schlossman, R
    Munshi, N
    Avigan, D
    Jagannath, S
    Alsina, M
    Doss, D
    McKenney, M
    Hande, K
    Farrell, M
    Gorelik, S
    Colson, K
    Warren, D
    Lunde, L
    Michelle, R
    Cole, G
    Mitsiades, C
    Hideshima, T
    Myers, T
    Knight, R
    Anderson, K
    BLOOD, 2005, 106 (11) : 110A - 111A
  • [34] A Phase I-II Study of the Combination of Bendamustine and Pomalidomide with Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma.
    Gasparetto, Cristina
    Green, Michael
    Srinivasan, Anandgopal
    Kang, Yubin
    Rizzieri, David A.
    Decastro, Carlos
    Diehl, Louis F.
    Beaven, Anne
    Li, Zighuo
    Rao, Arati V.
    Garrett, Anderson
    Tuchman, Sascha
    Long, Gwynn D.
    BLOOD, 2015, 126 (23)
  • [35] A phase I-II trial of bortezomib plus oral cyclophosphamide and prednisone for relapsed/refractory multiple myeloma.
    Reece, Donna E.
    Piza, Giovanni
    Trudel, Suzanne
    Pantoja, Manela
    Chen, Christine
    Mikhael, Joseph R.
    Kukreti, Vishal
    Stewart, Keith
    BLOOD, 2006, 108 (11) : 1009A - 1009A
  • [36] Phase Ib Study of Panobinostat and Bortezomib in Relapsed or Relapsed and Refractory Multiple Myeloma
    San-Miguel, Jesus F.
    Richardson, Paul G.
    Guenther, Andreas
    Sezer, Orhan
    Siegel, David
    Blade, Joan
    LeBlanc, Richard
    Sutherland, Heather
    Sopala, Monika
    Mishra, Kaushal K.
    Mu, Song
    Bourquelot, Priscille M.
    Victoria Mateos, Maria
    Anderson, Kenneth C.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (29) : 3696 - +
  • [37] A Phase II Study of Elotuzumab in Combination with Pomalidomide, Bortezomib, and Dexamethasone in Relapsed and Refractory Multiple Myeloma
    Yee, Andrew J.
    Laubach, Jacob P.
    Campagnaro, Erica L.
    Lipe, Brea C.
    Nadeem, Omar
    Friedman, Robb S.
    Cole, Craig E.
    O'Donnell, Elizabeth K.
    Bianchi, Giada
    Branagan, Andrew R.
    Shapiro, Samantha J.
    Harrington, Cynthia C.
    Burke, Jill N.
    Gammon, Marilyn T.
    Lively, Kathleen J.
    Thorburn, Cassandra A.
    Mann, Mason L.
    Lohr, Jens G.
    Anderson, Kenneth C.
    Richardson, Paul G.
    Raje, Noopur S.
    BLOOD, 2019, 134
  • [38] A phase 2 study of ibrutinib in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma
    Hajek, Roman
    Pour, Ludek
    Ozcan, Muhit
    Sanchez, Jesus Martin
    Sanz, Ramon Garcia
    Anagnostopoulos, Achilles
    Oriol, Albert
    Cascavilla, Nicola
    Terjung, Andreas
    Lee, Yihua
    Briso, Eva M.
    Dobkowska, Edyta
    Hauns, Bernhard
    Spicka, Ivan
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2020, 104 (05) : 435 - 442
  • [39] Cyclophosphamide, bortezomib, and dexamethasone (CYBORD) treatment for relapsed/refractory multiple myeloma.
    Monge, Jorge
    Kortuem, K. Martin
    Stewart, A. Keith
    Bergsagel, P. Leif
    Mikhael, Joseph
    Reeder, Craig B.
    Mayo, Angela
    Fonseca, Rafael
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [40] Bortezomib is cost-effective for the treatment of relapsed and refractory multiple myeloma.
    Mehta, J
    Duff, S
    Gupta, S
    BLOOD, 2003, 102 (11) : 500A - 501A
12345